225
Views
4
CrossRef citations to date
0
Altmetric
Note

1,10-seco guaianolide-type sesquiterpenoids from Chrysanthemum indicum

, , , , , , , & show all
Pages 877-883 | Received 29 Apr 2020, Accepted 22 Jun 2020, Published online: 30 Jun 2020
 

ABSTACT

A chemical investigation of the whole plant of traditional Chinese medicine, Chrysanthemum indicum L., led to the discovery of six guaianolide-type sesquiterpenoids 1–6 with a 1,10-splited skeleton. The structure of the new compound 1 was established by extensive analysis of UV, IR, MS, NMR and ECD data. Compounds 3–6 are mutually stereoisomers with four chiral centers and their absolute configurations were determined by comparison of ECD spectra. The anti-inflammatory effects of these isolates on lipopolysaccharide (LPS)-induced nitric oxide (NO) were investigated in RAW 264.7 cells. Results showed that most of the compounds displayed NO production inhibitory activities with IC50 values ranged from 3.54 to 8.17 μM.

Graphical abstract

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The financial support from the Central Government Guide Local Science and Technology Development Funds (No.14104349), the National Natural Science Foundation of China (No.31300284), and Scientific and Technological Key Project in Henan Province (No.192102310438).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.